CVS Raises 2026 Profit View to $7.90-$8.10 as Aetna Recovery Lifts Q2
Updated
Updated · CNBC · Aug 5
CVS Raises 2026 Profit View to $7.90-$8.10 as Aetna Recovery Lifts Q2
3 articles · Updated · CNBC · Aug 5
Summary
$2.58 in adjusted EPS and $106.1 billion in revenue beat Wall Street forecasts by wide margins, prompting CVS to lift 2026 guidance to $7.90-$8.10 a share and at least $414 billion in revenue.
Aetna drove much of the upside: its medical benefit ratio improved to 87.4% from 89.9% a year earlier, beating the 89.8% analysts expected as the insurer managed elevated medical costs more effectively.
All three business units topped revenue estimates, with insurance at $37.54 billion, health services at $51.8 billion and retail pharmacy at $33.82 billion, reinforcing CVS's broader turnaround effort.
Shares still fell more than 6% in morning trading after executives said Caremark, the pharmacy benefit manager inside health services, is expected to see membership declines.
CVS said it remains cautious on the rest of the year because of high medical costs and broader economic risks, even as it announced an Eli Lilly deal to offer Zepbound and Foundayo through its app by early Q4.